Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
Latest Information Update: 12 Jun 2025
At a glance
- Drugs OmniMSC-AMI (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors Taiwan Bio Therapeutics
Most Recent Events
- 06 Jun 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
- 15 Feb 2024 Status changed from not yet recruiting to recruiting.
- 21 Feb 2023 New trial record